These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20150363)

  • 1. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
    Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
    Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
    Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
    N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
    Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
    Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
    Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
    J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
    Eminowicz GK; Raman R; Conibear J; Plowman PN
    J Laryngol Otol; 2012 Jan; 126(1):79-82. PubMed ID: 22004800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hearing improvement after bevacizumab for neurofibromatosis type 2.
    Guntinas-Lichius O
    N Engl J Med; 2009 Oct; 361(18):1809-10; author reply 1810-1. PubMed ID: 19864683
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
    Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
    Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
    Farschtschi S; Kollmann P; Dalchow C; Stein A; Mautner VF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3857-60. PubMed ID: 25794543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hearing improvement after bevacizumab for neurofibromatosis type 2.
    Diao JS; Xia WS; Guo SZ
    N Engl J Med; 2009 Oct; 361(18):1810; author reply 1810-1. PubMed ID: 19877310
    [No Abstract]   [Full Text] [Related]  

  • 11. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
    Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
    J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
    Lu VM; Ravindran K; Graffeo CS; Perry A; Van Gompel JJ; Daniels DJ; Link MJ
    J Neurooncol; 2019 Sep; 144(2):239-248. PubMed ID: 31254266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
    Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
    J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2.
    Riina HA; Burkhardt JK; Santillan A; Bassani L; Patsalides A; Boockvar JA
    Interv Neuroradiol; 2012 Jun; 18(2):127-32. PubMed ID: 22681725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.
    Huang V; Bergner AL; Halpin C; Merker VL; Sheridan MR; Widemann BC; Blakeley JO; Plotkin SR
    Otol Neurotol; 2018 Jun; 39(5):632-638. PubMed ID: 29649040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
    Fisher LM; Doherty JK; Lev MH; Slattery WH
    Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avastin scintigraphy in surveillance of bevacizumab treatment in a patient with neurofibromatosis type 2: a case report.
    Versleijen MW; Verbist BM; Mulder JJ; de Geus-Oei LF; van Herpen CM
    Clin Nucl Med; 2014 Mar; 39(3):277-80. PubMed ID: 24445270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
    Sverak P; Adams ME; Haines SJ; Levine SC; Nascene D; Sommer K; Dusenbery K; Huang TC; Moertel C
    Otolaryngol Head Neck Surg; 2019 Mar; 160(3):526-532. PubMed ID: 30373466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
    Plotkin SR; Allen J; Dhall G; Campian JL; Clapp DW; Fisher MJ; Jain RK; Tonsgard J; Ullrich NJ; Thomas C; Edwards LJ; Korf B; Packer R; Karajannis MA; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1498-1506. PubMed ID: 37010875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
    Karajannis MA; Legault G; Hagiwara M; Ballas MS; Brown K; Nusbaum AO; Hochman T; Goldberg JD; Koch KM; Golfinos JG; Roland JT; Allen JC
    Neuro Oncol; 2012 Sep; 14(9):1163-70. PubMed ID: 22844108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.